|Articles|January 18, 2002
CDER News 12/31/01 through 1/2/02
Author(s)BioPharm International Editors
Original manufacturing supplements, original efficacy supplements, original and resubmitted NDAs, and new and generic drug approvals.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
2
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
3
Welcome to CPHI Frankfurt 2025
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
